September 28, 2022
Alkermes Announces Launch of 5th Annual Alkermes Pathways Research Awards® Program
September 20, 2022
Alkermes Showcases Research from Psychiatry Portfolio at Psych Congress
July 27, 2022
Alkermes plc Reports Second Quarter 2022 Financial Results
Our company possesses a profound power to help shape a more inclusive and equitable society for all. We recognize the importance of our role. See what our valued co-leaders have to say about their involvement with Pride@Work, our employee resource group for LGBTQ+ employees and allies.
Alkermes employees work in the laboratory, in the clinic and in the community, seeking to make a positive impact on the lives of people living with complicated and difficult-to-treat diseases. For many of our employees, this work is also part of their personal mission to help improve outcomes for patients, families and communities.
Now in its sixth year, we are proud of the impact the Alkermes Inspiration Grants® program has made. Alkermes is currently reviewing this year's applications for creative and innovative programs that will make a difference for patient communities. Grant recipients will be announced later this year.
Olanzapine and samidorphan - Schizophrenia or Bipolar I Disorder (pediatric)
ALKS 2680 - Narcolepsy
Nemvaleukin alfa* - Platinum-Resistant Ovarian Cancer
Nemvaleukin alfa - Mucosal Melanoma